Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic charcot neuroarthropathy

Diabetic Medicine

Volumn 14, Issue 7, 1997, Pages 527-531

  Gough, A ^a,b   Abraha, H ^a   Li, F ^a   Purewal, T S ^a   Foster, A V M ^a   Watkins, P J ^a   Moniz, C ^a   Edmonds, M E ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Carboxyterminal propeptide (P1CP); Carboxyterminal telopeptide of type 1 collagen (1CTP); Charcot neuroarthropathy; Osteoblast; Osteoclast; Procollagen

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; PROCOLLAGEN;

ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC JOINT DISEASE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS;

ACUTE DISEASE; ADULT; AGED; ALKALINE PHOSPHATASE; ARTHROPATHY, NEUROGENIC; BIOLOGICAL MARKERS; CHRONIC DISEASE; COLLAGEN; DIABETIC FOOT; DIABETIC NEUROPATHIES; FEMALE; FOOT; HUMANS; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; PEPTIDE FRAGMENTS; PROCOLLAGEN; SEX FACTORS; VEINS;

EID: 0030755451     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199707)14:7<527::AID-DIA404>3.0.CO;2-Q     Document Type: Article

References (44)

1. Cavanagh PR, Young MJ, Adams JE, Vickers KL, Boulton AJM. Bony abnormalities in the feet of neuropathic diabetic patients (oral presentation). In: Bakker K, ed. The Diabetic Foot: First International Symposium and Workshop. Amsterdam: Excerpta Medica, 1991: 5.
2. Cofield RH, Morrison MJ, Beabout JW. Diabetic neuroarthropathy in the foot: patient characteristics and patterns of radiographic change. Foot Ankle 1983; 4: 15-22.
3. Bruckner FE, Howell A. Neuropathic joints. Semin Arthritis Rheum 1972; 2: 47-49.
4. Johnson JTH. Neuropathic fractures and joint injuries. Pathogenesis and rationale of prevention and treatment. J Bone Joint Surg 1967; 49A: 1-30.
5. Slowman-Kovacs SD, Braunstein EM, Brandt KD. Rapidly progressive Charcot arthropathy following minor joint trauma in patients with diabetic neuropathy. Arthritis Rheum 1990; 33: 412-417.
6. Brower AC, Allman RM. Pathogenesis of the neurotrophic joint: neurotraumatic vs neurovascular. Radiology 1981; 139: 349-354.
7. Edmonds ME, Clarke MB, Newton S, Barrett J, Watkins PJ. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 1985; 57: 843-855.
8. Johnson LC, Williams LE, Blard JH. Cervical spine subluxations and massive osteolysis in the upper extremities in rheumatoid arthritis. Arthritis Rheum 1966; 9: 348.
9. Brooks AP. The neuropathic foot in diabetes. Part II: Charcot's neuroarthropathy. Diabetic Med 1986; 3: 116-118.
10. Risteli J, Elomaa I, Niemi S, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
11. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type 1 collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-132.
12. Eriksen EF, Charles P, Mosekilde L, Risteli L, Risteli J. Cross-linked carboxy-terminal telopeptide of type 1 collagen in serum: a new bone resorption marker. J Bone Miner Res 1991; 6 (suppl 1): S243.
13. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodelling using biochemical indicators of type 1 collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.
14. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxy-terminal propeptide of human type 1 procollagen. Clin Chem 1990; 36: 1328-1332.
15. Pedersen BJ, Bonde M. Purification of human procollagen type 1 carboxy-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin Chem 1994; 40: 811-816.
16. Robins SP. Biochemical markers for assessing skeletal growth. Eur J Clin Nutr 1994; 28 (Suppl 1): S199-S209.
17. Charles P, Hasling C, Risteli L, Risteli J, Mosekilde L, Eriksen EF. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int 1992; 51: 406-411.
18. Sanders LJ, Murray-Leisure K. Infections of the diabetic foot. In: Abramson C, McCarthy, eds. Infectious Diseases of the Lower Extremity. Baltimore: Williams and Wilkins, 1991: 193-211.
19. Eymott MJ, Alavi A, Dalinka MK, Kyle CC. Bone scintigraphy in diabetic osteoarthropathy. Radiology 1981; 140: 455-475.
20. Hetherington VJ. Technetium and combined gallium and technetium scans in the neuropathic foot. J Amer Podiat Assoc 1982; 72: 458-463.
21. Seabold JE, Flickinger FW, Kao SC, Gleason TJ, Kahn D, Nepola JV, Marsh JL. Indium-111 leucocyte/technetium-99m-MDP bone and magnetic resonance imaging; difficulty in diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nucl Med 1990; 31: 549-556.
22. Yuh WTC, Corson JD, Baraniewski HM, Rezai K, Shamma AR, Kathol MH, et al. Osteomyelitis of the foot in diabetic patients. Evaluation with plain films, 99m Tc-MDP bone scintigraphy and MR imaging. A J R 1989; 152: 795-800.
23. Beltran J, Scott Campanini D, Knight C, McCalla M. The diabetic foot: magnetic resonance imaging evaluation. Skel Radiol 1990; 19: 37-41.
24. Ebeling PR, Peterson JM, Riggs BL. Utility of type 1 procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-1250.
25. De la Piedra C, Diaz-Martin MA, Diaz-Diego EM, Lopez-Gavilanes E, Gonzalez-Parra E, Caramelo C, et al. Serum concentrations of carboxy-terminal cross-linked telopeptide of type 1 collagen (1CTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand J Clin Lab Invest 1994; 54: 11-15.
26. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentrations of the cross-linked carboxy-terminal telopeptide of type 1 collagen (1CTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992; 66: 337-341.
27. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type 1 collagen degradation product (1CTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 1061-1064.
28. Filipponi P, Pedetti M, Beghe F, Giovagnini B, Miam M, Cristallini S. Effects of two different bisphosphonates on Paget's disease of bone: 1CTP assessed. Bone 1994; 15: 261-267.
29. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increase type 1 collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993; 52: 866-869.
30. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Costantini S, Chicca S, De-Meo S, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10: 52-58.
31. Tessitore N, Bonucci E, D'Angelo A, Lund B, Valvo E, Lupo A, Loschiavo C, et al. Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 1984; 37: 153-159.
32. Korkor A, Schwartz J, Bergfield M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E. Absence of metabolic bone disease in adult patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1983; 56: 496-500.
33. Selby PL, Shearing PA, Marshall SM. Hydroxyproline excretion is increased in diabetes mellitus and related to the presence of microalbuminuria. Diabetic Med 1995; 12: 240-243.
34. Olmos JM, Perez-Castrillon JL, Garcia MT, Garrido JC, Amado JA, Gonzalez-Macias. Bone densitometry and biochemical bone remodelling markers in type 1 diabetes mellitus. Bone Miner 1994; 26: 1-8.
35. Silveiro SP, Friedman R, Gross JL. Glomerular hyperfiltration in NIDDM without overt proteinuria. Diabetes Care 1993; 16: 115-119.
36. Vora JP, Dohlen J, Dean JD, Thomas D, Williams JD, Owens DR, Peters JR. Renal haemodynamics in newly presenting non-insulin-dependent diabetes mellitus. Kidney Int 1992; 41: 829-835.
37. Smedsrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345-350.
38. Jensen LT, Olesen HP, Risteli J, Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long-term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990; 40: 620-624.
39. Hamdy NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, Kanis JA. Serum type 1 procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994; 9: 511-516.
40. Fleischmajer R, Timpl R, Tuderman L, Raisher L, Wiestner M, Perlish JS, et al. Ultrastructural identification of extension aminopropeptides of type I and type III procollagens in human skin. Proc Natl Acad Sci USA 1981; 78: 7360-7364.
41. Robey PG, Fisher LW, Young MF, Termine JD. The biochemistry of bone. In: Riggs BL, Melton III LJ, eds. Osteoporosis. New York: Raven Press, 1988: 95-109.
42. Philipov JP, Pascalev MD, Aminkov BY, Grosev CD. Changes in serum carboxy-terminal telopeptide of type 1 collagen in an experimental model of canine osteomyelitis. Calcif Tissue Int 1995; 57: 152-154.
43. Edelson GW, Jensen JL, Kaczynski R. Comparison of urinary hydroxypyridinium crosslinks in diabetics with Charcot foot disease versus osteomyelitis (Abstract). Diabetes 1996; 45 (suppl 2): 108A.
44. Selby PL, Young MJ, Boulton AJM. Bisphosphonates - a new treatment for diabetic Charcot neuroarthropathy? Diabetic Med 1994; 11: 28-31.